Contents

Preface

Chapter 1
The place of gynaecologic cancers in peritoneal surface oncology concept
Naoual Bakrin and Olivier Glehen

Chapter 2
Surgical anatomy of upper abdominal solid organs for gynecologic oncologists
Yusuf Yildirim and Emre Gultekin

Chapter 3
Cytoreductive surgery for ovarian cancer
Philipp Harter, Jacobus Pfisterer and Andreas du Bois

Chapter 4
Surgical and chemotherapeutic cytoreduction for advanced primary and recurrent ovarian cancer, the Washington Cancer Institute approach
Paul H. Sugarbaker

Chapter 5
Hyperthermic intraperitoneal chemotherapy (HIPEC) in optimally cytoreduced peritoneal carcinomatosis of gynecology origin: Does it provide survival advantage?
Eelco de Bree, Dimitris D. Tsiftsis and John Melissas

Chapter 6
The role of cytoreductive surgery for non-genital tract metastases to the ovary
Leszek Gottwald, Janusz Piekarski and Arkadiusz Jeziorski
Chapter 7
Cytoreductive surgery in endometrial cancer and uterine sarcomas
Stefanie M. Ueda and Robert E. Bristow
123

Chapter 8
The role of surgery in the management of high-risk gestational
trophoblastic neoplasia
John R. Lurain
153

Chapter 9
The role of cytoreductive surgery in cervical cancer: Is there a
benefit of retroperitoneal lymph node debulking in advanced disease?
Waldo Jiménez and Allan Covens
161

Chapter 10
The role of cytoreductive surgery in vulvar cancer. Is there an
indication for aggressive surgical approach in FIGO
Stage III/IV disease?
Anthony Proietto and Ganendra Raj
173

Chapter 11
The place of pelvic exenteration as a cytoreductive procedure in
advanced gynaecologic malignancies
Markus C. Fleisch, Daniel T. Rein and Wolfgang Janni
179

Chapter 12
The role of video-assisted thoracic surgery (VATS) and
intrathoracic cytoreductive surgery in gynecologic malignancies
John P. Diaz and Dennis S. Chi
201

Chapter 13
Laparoscopic and robotic assisted laparoscopic cytoreductive
surgery in gynecologic oncology
Frédéric Marchal, Philippe Rauch and François Guillemín
213

Chapter 14
Critical care and pain management in patients who have undergone
cytoreductive surgery for gynecologic malignancies
A. Le Gouez, J. Dick and D. Benhamou
233
Preface

Despite the crucial advancements in treatment with chemotherapy, radiotherapy and biological agents, main treatment method in gynecologic cancers is surgery as in all other solid tumors.

The history of gynecologic cancers is very old. Evidences of first human gynecologic cancers were discovered in Egyptian mummies from the 3000 BC. Granville (1826) dissected mummified remains and discovered an ovarian mass later thought to be a malignant cystadenocarcinoma of the ovary. The history of cytoreductive surgery in gynecologic cancers goes back to the end of the 18th century. The application of modern cytoreductive surgery in gynecologic cancers was initiated in 1834 by Meigs. Later, significant progress was made in cytoreductive surgery by the studies performed by the Gynecologic Oncology Group (GOG) and the International Federation of Gynecology and Obstetrics (FIGO) and many other authors. Currently, resection of almost every organ is performed for cytoreductive surgery of ovarian cancer and every day we witness new technical improvements enforcing the limits of our imagination. Besides, cytoreductive surgery has been applied not only in the treatment of ovarian-fallopian-peritoneal cancers, but also in the treatment of endometrial and other gynecologic cancers. Theoretical rationale of cytoreductive surgery is to improve the chemotherapy response (by reducing tumor load before chemotherapy, increasing tumor perfusion and growth fraction), to improve the immune function and to make possible changes in tumor biology.

One of the other recent advances in Gynecologic Oncology is that ovarian cancer has constituted a model within the concept of “Peritoneal Surface Oncology” (Cytoreductive Surgery combined with Hyperthermic Intraperitoneal Chemotherapy-HIPEC) which has been developed since 1990’s for the treatment of peritoneal carcinomatosis. This approach is gradually becoming the standard management both for gynecologic and non-gynecologic peritonitis carcinomatosis cases. Scientific studies on the extensive cytoreductive surgery of ovarian cancer have played a significant role in the development of this concept.

This book aims to introduce the role of cytoreductive surgery in gynecologic cancers through a multi-disciplinary approach. Many famous scientists from US, Canada, European Countries and Australia have participated in this special work. I would like to express my heartfelt thanks to all authors and co-authors who contributed to this book by sparing their valuable time in spite of their busy academic schedules. It has been my pleasure to work with them in this project and I look forward to working together again in other projects in the future.
I hope this book to be useful for the specialists, fellowships and assistants in all disciplines related to the treatment of gynecologic cancers.
I dedicate this book to my beloved wife and son.

January 2010

Yusuf Yildirim

Izmir
With advancements in surgical techniques, equipment, and postoperative care, cytoreductive surgery has become a viable option for the treatment of PC. The peritoneum is considered an intra-abdominal organ that is amenable to resection called Cytoreductive Surgery (CRS). Request PDF on ResearchGate | Laparoscopic surgery in gynecological oncology | The use of laparoscopic staging and/or surgery in the field of gynaecological oncology was pioneered in the late 1980s and the first reports were published in the early 1990s. The issue has been initially most controversial, and is still debated, with some justification...Â The roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and palliative surgery are reviewed. The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed. View.Â Laparoscopic management of complications in gynecologic laparoscopic surgery is feasible and efficient. View. Document Detail. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. MedLine Citation: PMID: 9264559 Owner: NLM Status: MEDLINE. Abstract/OtherAbstract: Reports which analyzed the effects of secondary cytoreductive surgery at second-look laparotomy have often included small numbers of patients who have been treated with a variety of first-line chemotherapy regimens and those who may have progressed on first-line therapy. The purpose of this study was to analyze survival following secondary cytoreductive surgery at second-look laparotomy.